Huang Ning, Wang Di, Zhu Tian-Tian, Ge Xiao-Yue, Liu Hong, Yao Mao-Zhong, Guo Yan-Zi, Peng Jun, Wang Qing, Zhang Zheng, Hu Chang-Ping
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410078, China; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan 450052, China.
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410078, China.
Biochem Pharmacol. 2023 Jan;207:115350. doi: 10.1016/j.bcp.2022.115350. Epub 2022 Nov 23.
The pulmonary vascular remodeling (PVR), the pathological basis of pulmonary hypertension (PH), entails pulmonary artery smooth muscle cells (PASMCs) phenotypic switching, but appreciation of the underlying mechanisms is incomplete. Exosomes, a novel transfer machinery enabling delivery of its cargos to recipient cells, have been recently implicated in cardiovascular diseases including PH. The two critical questions of whether plasma-derived exosomes drive PASMCs phenotypic switching and what cargo the exosomes transport, however, remain unclear. Herein, by means of transmission electron microscopy and protein detection, we for the first time, characterized lectin like oxidized low-density lipoprotein receptor-1 (LOX-1) as a novel cargo of plasma-derived exosomes in PH. With LOX-1 knockout (Olr1) rats-derived exosomes, we demonstrated that exosomal LOX-1 could be transferred into PASMCs and thus elicited cell phenotypic switching. Of importance, Olr1 rats exhibited no cell phenotypic switching and developed less severe PH, but administration of wild type rather than Olr1 exosomes to Olr1 rats recapitulated the phenotype of PH with robust PASMCs phenotypic switching. We also revealed that exosomal LOX-1 triggered PASMCs phenotypic switching, PVR and ultimately PH via ERK1/2-KLF4 signaling axis. This study has generated proof that plasma-derived exosomes confer PH by delivering LOX-1 into PASMCs. Hence, exosomal LOX-1 represents a novel exploitable target for PH prevention and treatment.
肺血管重塑(PVR)是肺动脉高压(PH)的病理基础,涉及肺动脉平滑肌细胞(PASMCs)的表型转换,但对其潜在机制的认识尚不完全。外泌体是一种能够将其携带物传递给受体细胞的新型转运机制,最近已被证明与包括PH在内的心血管疾病有关。然而,血浆来源的外泌体是否驱动PASMCs表型转换以及外泌体运输何种携带物这两个关键问题仍不清楚。在此,通过透射电子显微镜和蛋白质检测,我们首次将凝集素样氧化低密度脂蛋白受体-1(LOX-1)鉴定为PH中血浆来源外泌体的一种新型携带物。利用LOX-1基因敲除(Olr1)大鼠来源的外泌体,我们证明外泌体LOX-1可以转移到PASMCs中,从而引发细胞表型转换。重要的是,Olr1大鼠没有表现出细胞表型转换,并且发生的PH较轻,但给Olr1大鼠注射野生型而非Olr1外泌体可重现PH的表型,并伴有强烈的PASMCs表型转换。我们还发现,外泌体LOX-1通过ERK1/2-KLF4信号轴触发PASMCs表型转换、PVR并最终导致PH。这项研究证明了血浆来源的外泌体通过将LOX-1传递到PASMCs中导致PH。因此,外泌体LOX-1代表了一种用于PH预防和治疗的新型可开发靶点。